Molecular Factors and Pathways of Hepatotoxicity Associated with HIV/SARS-CoV-2 Protease Inhibitors

• Published in: International journal of molecular sciences Vol. 24; no. 9; p. 7938
• Main Author: Ji, Cheng
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 27.04.2023; MDPI
• Subjects: Acquired immune deficiency syndrome; AIDS; Alcohol use; Anti-HIV agents; Antiviral agents; Antiviral Agents - adverse effects; Antiviral Agents - chemistry; Antiviral drugs; Apolipoproteins; Atazanavir; Chemical and Drug Induced Liver Injury; Coronaviruses; COVID-19; Darunavir; Drug therapy; Fosamprenavir; Health aspects; HIV; HIV (Viruses); HIV infection; HIV Infections - complications; HIV Infections - drug therapy; HIV Protease Inhibitors - pharmacology; Human immunodeficiency virus; Humans; Infection; Insulin; Insulin resistance; Isoenzymes; Kinases; Liver; Protease Inhibitors - pharmacology; Proteases; Reactive oxygen species; Review; SARS-CoV-2; unfolded protein response; liver disease; anti-AIDS/COVID-19 drugs; ER/Golgi stress; alcohol use disorder (AUD); side effects; substance use disorders (SUD); safer drug design

Antiviral protease inhibitors are peptidomimetic molecules that block the active catalytic center of viral proteases and, thereby, prevent the cleavage of viral polyprotein precursors into maturation. They continue to be a key class of antiviral drugs that can be used either as boosters for other cl...